116 related articles for article (PubMed ID: 3494771)
1. Control of B cell proliferation: arrest of B cells in late G1 underlies immunosuppression induced by plasma cell tumors.
Berman JE; Zolla-Pazner S
J Immunol; 1987 May; 138(9):2805-12. PubMed ID: 3494771
[TBL] [Abstract][Full Text] [Related]
2. Immune dysfunction in mice with plasmacytomas. I. Evidence that transforming growth factor-beta contributes to the altered expression of activation receptors on host B lymphocytes.
Berg DJ; Lynch RG
J Immunol; 1991 Apr; 146(8):2865-72. PubMed ID: 1826699
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the clonal diversity of the B cell repertoires in adult mice that differ in the expression of cell surface IgD.
Fultz MJ; Finkelman FD; Metcalf ES
Eur J Immunol; 1987 Aug; 17(8):1137-43. PubMed ID: 3113979
[TBL] [Abstract][Full Text] [Related]
4. Acquisition of surface IgD fails to protect from tolerance-induction. Both surface IgM- and surface IgD-mediated signals induce apoptosis of immature murine B lymphocytes.
Norvell A; Monroe JG
J Immunol; 1996 Feb; 156(4):1328-32. PubMed ID: 8568230
[TBL] [Abstract][Full Text] [Related]
5. G0 B cells activated by anti-mu acquire the ability to proliferate in response to B cell-activating factors independently from entry into G1 phase.
Proust JJ; Chrest FJ; Buchholz MA; Nordin AA
J Immunol; 1985 Nov; 135(5):3056-61. PubMed ID: 3900202
[TBL] [Abstract][Full Text] [Related]
6. Effects of neonatal anti-delta antibody treatment on the murine immune system. I. Suppression of development of surface IgD+ B cells and expansion of a surface IgM+ IgD- B lymphocyte population.
Finkelman FD; Mond JJ; Metcalf ES
J Immunol; 1983 Aug; 131(2):593-600. PubMed ID: 6602840
[TBL] [Abstract][Full Text] [Related]
7. Separate control of B lymphocyte early activation and proliferation in response to anti-IgM antibodies.
DeFranco AL; Raveche ES; Paul WE
J Immunol; 1985 Jul; 135(1):87-94. PubMed ID: 3873499
[TBL] [Abstract][Full Text] [Related]
8. Size-dependent B lymphocyte subpopulations: relationship of cell volume to surface phenotype, cell cycle, proliferative response, and requirements for antibody production to TNP-Ficoll and TNP-BA.
Thompson CB; Scher I; Schaefer ME; Lindsten T; Finkelman FD; Mond JJ
J Immunol; 1984 Nov; 133(5):2333-42. PubMed ID: 6207226
[TBL] [Abstract][Full Text] [Related]
9. Sequential requirements for cell cycle progression of resting human B cells after activation by anti-Ig.
Muraguchi A; Kehrl JH; Butler JL; Fauci AS
J Immunol; 1984 Jan; 132(1):176-80. PubMed ID: 6197443
[TBL] [Abstract][Full Text] [Related]
10. Lymphoma models for B cell activation and tolerance. VI. Reversal of anti-Ig-mediated negative signaling by T cell-derived lymphokines.
Scott DW; O'Garra A; Warren D; Klaus GG
J Immunol; 1987 Dec; 139(12):3924-9. PubMed ID: 3500976
[TBL] [Abstract][Full Text] [Related]
11. B cells from M167 mu kappa transgenic mice fail to proliferate after stimulation with soluble anti-Ig antibodies. A model for antigen-induced B cell anergy.
Sieckmann DG; Holmes K; Hornbeck P; Martin E; Guelde G; Bondada S; Longo DL; Kenny JJ
J Immunol; 1994 May; 152(10):4873-83. PubMed ID: 8176209
[TBL] [Abstract][Full Text] [Related]
12. IL-10 inhibits lipopolysaccharide-induced murine B cell proliferation and cross-linking of surface antigen receptors or ligation of CD40 restores the response.
Marcelletti JF
J Immunol; 1996 Oct; 157(8):3323-33. PubMed ID: 8871628
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of c-fos inhibits down-regulation of a cyclin-dependent kinase-2 inhibitor p27Kip1 in splenic B cells activated by surface Ig cross-linking.
Kobayashi K; Phuchareon J; Inada K; Tomita Y; Koizumi T; Hatano M; Miyatake S; Tokuhisa T
J Immunol; 1997 Mar; 158(5):2050-6. PubMed ID: 9036948
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory mechanism of the proliferative responses of resting B cells: feedback regulation by a lymphokine (suppressive B-cell factor) produced by Fc receptor-stimulated B cells.
Ohno T; Miyama-Inaba M; Masuda T; Fukuma K; Ajisaka K; Suzuki R; Kumagai K; Kanoh T; Uchino H
Immunology; 1987 May; 61(1):35-41. PubMed ID: 2953673
[TBL] [Abstract][Full Text] [Related]
15. B cell tolerance induction by cross-linking of membrane IgM, but not IgD, and synergy by cross-linking of both isotypes.
Gaur A; Yao XR; Scott DW
J Immunol; 1993 Mar; 150(5):1663-9. PubMed ID: 8436810
[TBL] [Abstract][Full Text] [Related]
16. Differential expression of cell activation markers after stimulation of resting human B lymphocytes.
Kehrl JH; Muraguchi A; Fauci AS
J Immunol; 1984 Jun; 132(6):2857-61. PubMed ID: 6427329
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of B-lymphocyte clonal proliferation by spleen cells from plasmacytoma-bearing mice.
Hamburger AW
J Natl Cancer Inst; 1980 Dec; 65(6):1337-43. PubMed ID: 6968847
[TBL] [Abstract][Full Text] [Related]
18. B lymphocyte activation: entry into cell cycle is accompanied by decreased expression of IgD but not IgM.
Monroe JG; Havran WL; Cambier JC
Eur J Immunol; 1983 Mar; 13(3):208-13. PubMed ID: 6601015
[TBL] [Abstract][Full Text] [Related]
19. B cell activation. V. Differentiation signaling of B cell membrane depolarization, increased I-A expression, G0 to G1 transition, and thymidine uptake by anti-IgM and anti-IgD antibodies.
Cambier JC; Monroe JG
J Immunol; 1984 Aug; 133(2):576-81. PubMed ID: 6610706
[TBL] [Abstract][Full Text] [Related]
20. Surface immunoglobulin phenotype of complement receptor-positive and complement receptor-negative B cells of normal and xid immunodeficient mice.
Lindsten T; Finkelman FD; Thompson CB; Andersson B; Scher I
Eur J Immunol; 1984 Apr; 14(4):329-35. PubMed ID: 6609823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
